Advertisement

Tumor Biology

, Volume 37, Issue 9, pp 11815–11824 | Cite as

High miR-96 levels in colorectal adenocarcinoma predict poor prognosis, particularly in patients without distant metastasis at the time of initial diagnosis

  • Stamatia-Maria Rapti
  • Christos K. Kontos
  • Iordanis N. Papadopoulos
  • Andreas Scorilas
Original Article

Abstract

MicroRNA-96 (miR-96) is an oncomiR that facilitates the development of malignant tumors by promoting growth, proliferation, and survival of cancer cells. Previous studies using high-throughput techniques have shown that miR-96 is upregulated in colorectal cancer compared to adjacent normal colorectal tissue. The aim of this study was the investigation of the potential clinical value of miR-96 as a molecular prognostic biomarker in colorectal adenocarcinoma. For this purpose, total RNA was extracted from 108 primary colorectal adenocarcinoma samples and 54 paired non-cancerous colorectal tissue specimens. After polyadenylation and reverse transcription, miR-96 molecules were determined using an in-house developed real-time quantitative PCR based on SYBR Green chemistry. Calculations were carried out with the comparative CT method, using SNORD48 as endogenous reference gene. Finally, extensive biostatistical analysis was performed and showed that miR-96 is significantly upregulated in colorectal adenocarcinoma specimens compared to their non-cancerous counterparts (p < 0.001) as well as in tumors having invaded regional lymph nodes (p = 0.009) and those of advanced TNM stage (p = 0.008). miR-96 expression is an unfavorable prognostic marker in colorectal adenocarcinoma, predicting poor disease-free and overall survival (p = 0.041 and 0.028, respectively), independently of classical clinicopathological parameters. Most importantly, miR-96 expression stratifies patients without distant metastasis (M0) at the time of diagnosis into two groups with substantially different prognosis (p = 0.040). In conclusion, high tissue levels of miR-96 are associated with advanced stages of colorectal adenocarcinoma and predict an increased risk for disease recurrence and poor overall survival, especially in patients without distant metastasis at the time of diagnosis.

Keywords

MicroRNAs (miRNAs) Molecular tumor markers Prognostic biomarkers Colorectal cancer Real-time quantitative PCR (qPCR) 

Notes

Compliance with ethical standards

The study was approved by the institutional Ethics Committee of the University General Hospital “Attikon” in accordance with the ethical standards of the Declaration of Helsinki and informed consent was obtained from the patients.

Conflicts of interest

The authors declare that they have no conflict of interest.

Supplementary material

13277_2016_5023_Fig4_ESM.gif (59 kb)
ESM 1

(GIF 58 kb)

13277_2016_5023_MOESM1_ESM.tif (563 kb)
High resolution image (TIF 562 kb)
13277_2016_5023_MOESM2_ESM.doc (84 kb)
ESM 2 (DOC 84 kb)

References

  1. 1.
    Boyle P, Levin B. Colorectal cancer. In world cancer report. International Agency for Research on Cancer. 2008:374-8.Google Scholar
  2. 2.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMedGoogle Scholar
  3. 3.
    Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975;36:2251–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Schoen RE. Families at risk for colorectal cancer: risk assessment and genetic testing. J Clin Gastroenterol. 2000;31:114–20.CrossRefPubMedGoogle Scholar
  5. 5.
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.CrossRefPubMedGoogle Scholar
  6. 6.
    Pokorny RM, Hunt L, Galandiuk S. What’s new with tumor markers for colorectal cancer? Dig Surg. 2000;17:209–15.CrossRefPubMedGoogle Scholar
  7. 7.
    Duffy MJ, van Dalen A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European group on tumour markers (egtm) guidelines. Eur J Cancer. 2003;39:718–27.CrossRefPubMedGoogle Scholar
  8. 8.
    Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Ambros V, Lee RC, Lavanway A, Williams PT, Jewell D. Micrornas and other tiny endogenous rnas in C. elegans. Curr Biol. 2003;13:807–18.CrossRefPubMedGoogle Scholar
  10. 10.
    Calin GA, Sevignani C, Dumitru CD, et al. Human microrna genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Melo SA, Esteller M. Dysregulation of micrornas in cancer: playing with fire. FEBS Lett. 2011;585:2087–99.CrossRefPubMedGoogle Scholar
  12. 12.
    Trabucchi M, Briata P, Filipowicz W, Rosenfeld MG, Ramos A, Gherzi R. How to control mirna maturation? RNA Biol. 2009;6:536–40.CrossRefPubMedGoogle Scholar
  13. 13.
    Kontos CK, Scorilas A, Papavassiliou AG. The role of transcription factors in laboratory medicine. Clin Chem Labo Med : CCLM / FESCC. 2013;51:1563–71.Google Scholar
  14. 14.
    Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482:347–55.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Schee K, Fodstad O, Flatmark K. MicroRNAs as biomarkers in colorectal cancer. Am J Pathol. 2010;177:1592–9.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Bandres E, Cubedo E, Agirre X, et al. Identification by real-time pcr of 13 mature micrornas differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;5:29.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Schaefer A, Jung M, Mollenkopf HJ, et al. Diagnostic and prognostic implications of microrna profiling in prostate carcinoma. Int J Cancer. 2010;126:1166–76.PubMedGoogle Scholar
  18. 18.
    Lin H, Dai T, Xiong H, et al. Unregulated mir-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor foxo3a. PLoS One. 2010;5:e15797.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Wang L, Zhu MJ, Ren AM, et al. A ten-microRNA signature identified from a genome-wide microrna expression profiling in human epithelial ovarian cancer. PLoS One. 2014;9:e96472.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Leung WK, He M, Chan AW, Law PT, Wong N. Wnt/beta-catenin activates mir-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. Cancer Lett. 2015;362:97–105.CrossRefPubMedGoogle Scholar
  21. 21.
    Ma L, Huang Y, Zhu W, et al. An integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers. PLoS One. 2011;6:e26502.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Tanaka M, Suzuki HI, Shibahara J, et al. Evi1 oncogene promotes kras pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Oncogene. 2014;33:2454–63.CrossRefPubMedGoogle Scholar
  23. 23.
    Gao F, Wang W. MicroRNA-96 promotes the proliferation of colorectal cancer cells and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein o1 (foxo1) and foxo3a. Mol Med Rep. 2015;11:1200–6.PubMedGoogle Scholar
  24. 24.
    Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. Mirecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009;37:D105–10.CrossRefPubMedGoogle Scholar
  25. 25.
    Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care? Nat Rev Clin Oncol. 2012;9:119–23.CrossRefGoogle Scholar
  26. 26.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method. Methods. 2001;25:402–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative c(t) method. Nat Protoc. 2008;3:1101–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Mlcochova J, Faltejskova P, Nemecek R, Svoboda M, Slaby O. MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J Cancer Res Clin Oncol. 2013.Google Scholar
  30. 30.
    Ma Q, Wang X, Li Z, et al. MicroRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway. Oncol Rep. 2013;29:1652–8.PubMedGoogle Scholar
  31. 31.
    Ma Y, Li W, Wang H. Roles of miRNA in the initiation and development of colorectal carcinoma. Curr Pharm Des. 2013;19:1253–61.PubMedGoogle Scholar
  32. 32.
    Yamada N, Noguchi S, Mori T, Naoe T, Maruo K, Akao Y. Tumor-suppressive microRNA-145 targets catenin delta-1 to regulate wnt/beta-catenin signaling in human colon cancer cells. Cancer Lett. 2013;335:332–42.CrossRefPubMedGoogle Scholar
  33. 33.
    Nagel R, le Sage C, Diosdado B, et al. Regulation of the adenomatous polyposis coli gene by the mir-135 family in colorectal cancer. Cancer Res. 2008;68:5795–802.CrossRefPubMedGoogle Scholar
  34. 34.
    Yu Y, Kanwar SS, Patel BB, et al. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. Carcinogenesis. 2012;33:68–76.CrossRefPubMedGoogle Scholar
  35. 35.
    Schetter AJ, Harris CC. Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol. 2011;38:734–42.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Menendez P, Villarejo P, Padilla D, Menendez JM, Rodriguez-Montes JA. Implications of the histological determination of microRNAs in the screening, diagnosis and prognosis of colorectal cancer. J Surg Oncol. 2013;108:70–3.CrossRefPubMedGoogle Scholar
  37. 37.
    Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 2013;4:116.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Bartley AN, Yao H, Barkoh BA, et al. Complex patterns of altered microrna expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer. Clin Cancer Res. 2011;17:7283–93.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Wu CW, Ng SS, Dong YJ, et al. Detection of mir-92a and mir-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 2012;61:739–45.CrossRefPubMedGoogle Scholar
  40. 40.
    Xiao YF, Yong X, Fan YH, Lu MH, Yang SM, Hu CJ. MicroRNA detection in feces, sputum, pleural effusion and urine: novel tools for cancer screening (review). Oncol Rep. 2013;30:535–44.PubMedGoogle Scholar
  41. 41.
    Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, et al. Differential expression of mir-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol. 2011;46:1391–402.CrossRefPubMedGoogle Scholar
  42. 42.
    Zhang QH, Sun HM, Zheng RZ, et al. Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues. Gene. 2013;527:26–32.CrossRefPubMedGoogle Scholar
  43. 43.
    Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A, Yakhini Z. Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One. 2009;4:e8003.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Kara M, Yumrutas O, Ozcan O, et al. Differential expressions of cancer-associated genes and their regulatory miRNAs in colorectal carcinoma. Gene. 2015;567:81–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Hamfjord J, Stangeland AM, Hughes T, et al. Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS One. 2012;7:e34150.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Ress AL, Stiegelbauer V, Winter E. Mir-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients. Mol Carcinog. 2014.Google Scholar
  47. 47.
    Zhang Q, Ren W, Huang B, Yi L, Zhu H. MicroRNA-183/182/96 cooperatively regulates the proliferation of colon cancer cells. Mol Med Rep. 2015;12:668–74.PubMedGoogle Scholar
  48. 48.
    Xu XM, Qian JC, Deng ZL, et al. Expression of mir-21, mir-31, mir-96 and mir-135b is correlated with the clinical parameters of colorectal cancer. Oncol Lett. 2012;4:339–45.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Li J, Li P, Chen T, et al. Expression of microRNA-96 and its potential functions by targeting foxo3 in non-small cell lung cancer. Tumour Biol. 2015;36:685–92.CrossRefPubMedGoogle Scholar
  50. 50.
    Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008;14:844–52.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Stamatia-Maria Rapti
    • 1
  • Christos K. Kontos
    • 1
  • Iordanis N. Papadopoulos
    • 2
  • Andreas Scorilas
    • 1
  1. 1.Department of Biochemistry and Molecular BiologyUniversity of AthensAthensGreece
  2. 2.Fourth Surgery DepartmentUniversity General Hospital “Attikon”AthensGreece

Personalised recommendations